Listing 14.10 Sjogren's Syndrome in 2026: How SSA Evaluates Primary Sjogren's, the Anti-Ro and Anti-La Antibody Framework, the Two-Path Rule, and Why Dry Eyes and Dry Mouth Alone Are Not Enough
Sjogren's syndrome is one of the most under-recognized autoimmune diseases. Dry eyes and dry mouth are the classic features, but Sjogren's is a systemic illness that can hit lungs, kidneys, nerves, joints, blood counts, and cognitive function. When it goes systemic, it can be truly disabling. That is exactly what Listing 14.10 exists for.
Here is the plain version. To meet 14.10, you need either Path A (two organs involved with one at moderate severity, plus two constitutional symptoms) or Path B (repeated manifestations plus two constitutional symptoms plus one marked functional limitation). Same structure as 14.02 lupus, 14.04 scleroderma, 14.05 myositis, and 14.06 UCTD/MCTD. What is different is the underlying disease pattern.
See If You Qualify
The exact text of Listing 14.10
14.10 Sjogren's syndrome. As described in 14.00D7. With:
A. Involvement of two or more organs/body systems, with:
1. One of the organs/body systems involved to at least a moderate level of severity; and
2. At least two of the constitutional symptoms or signs (severe fatigue, fever, malaise, or involuntary weight loss).
OR
B. Repeated manifestations of Sjogren's syndrome, with at least two of the constitutional symptoms or signs (severe fatigue, fever, malaise, or involuntary weight loss) and one of the following at the marked level:
1. Limitation of activities of daily living.
2. Limitation in maintaining social functioning.
3. Limitation in completing tasks in a timely manner due to deficiencies in concentration, persistence, or pace.
How SSA defines Sjogren's under 14.00D7
SSA's definition tracks the current ACR/EULAR 2016 classification. Primary Sjogren's syndrome is characterized by:
- Xerostomia (dry mouth) with reduced salivary flow
- Keratoconjunctivitis sicca (dry eyes) with abnormal Schirmer test or ocular staining
- Positive anti-Ro (SSA) or anti-Ro/La antibodies, or characteristic minor salivary gland biopsy showing focal lymphocytic sialadenitis with a focus score of 1 or greater per 4 mm2
- Extra-glandular involvement in a significant portion of patients
Secondary Sjogren's occurs in the setting of another connective tissue disease (lupus, RA, scleroderma). When it is secondary, SSA still evaluates the sicca features under 14.10 but the underlying disease determines the primary listing route.
Path A broken down
Step 1: identify two involved organs or body systems
The sicca complex (dry eyes plus dry mouth) is one organ system involvement (exocrine/ocular). The second organ system must be something else. Common extra-glandular involvement includes:
- Musculoskeletal. Non-erosive inflammatory arthritis, myalgias, myositis
- Pulmonary. Interstitial lung disease (LIP or NSIP pattern), airways disease
- Renal. Interstitial nephritis with renal tubular acidosis, or glomerulonephritis
- Hematologic. Cytopenias, cryoglobulinemia, hypergammaglobulinemia
- Neurologic. Peripheral neuropathy (small fiber, sensory ataxia, mononeuritis multiplex), cranial neuropathy, CNS involvement
- Cutaneous. Purpura, urticarial vasculitis, annular erythema
- Cardiovascular. Pericarditis, pulmonary hypertension
- GI. Autoimmune pancreatitis, autoimmune hepatitis, primary biliary cholangitis
- Lymphoproliferative. MALT lymphoma (5 percent lifetime risk in primary Sjogren's)
Step 2: one organ system must be at moderate severity
Working examples of moderate severity:
- ILD with FVC 50 to 65 percent predicted or DLCO 40 to 55 percent
- Renal tubular acidosis requiring bicarbonate replacement and causing electrolyte disturbances
- Small fiber neuropathy with skin biopsy documenting low epidermal nerve fiber density and disabling burning pain
- Sensory ataxia impairing gait and requiring assistive device
- Chronic anemia with hemoglobin 8 to 10 g/dL from cytopenias
- MALT lymphoma requiring treatment
- Autoimmune hepatitis with elevated transaminases and requiring immunosuppression
Step 3: two constitutional symptoms
Section 14.00C defines the four: severe fatigue, fever, malaise, involuntary weight loss. Sjogren's fatigue is often the most disabling feature. Get it documented at multiple visits over time.
Path B broken down
Path B captures the patient whose disease flares repeatedly but does not sit at a fixed two-organ moderate-severity presentation. Sjogren's is a chronic waxing-waning disease. A patient may have arthritis in one flare, pulmonary symptoms in another, cytopenias in a third, and cognitive dysfunction throughout.
Path B requires:
- Repeated manifestations of Sjogren's
- Two constitutional symptoms
- One marked functional limitation in ADLs, social functioning, or completing tasks in a timely manner (CPP domain)
The CPP domain often applies to Sjogren's patients because of "Sjogren's brain fog" or documented cognitive dysfunction. Get a neuropsychological evaluation if this is your best path.
The antibody and biopsy framework
- Anti-Ro (SSA). Positive in about 70 percent of primary Sjogren's. Strong support for diagnosis.
- Anti-La (SSB). Positive in about 40 percent. Almost always coexists with anti-Ro.
- ANA. Positive in 80+ percent, usually speckled pattern.
- Rheumatoid factor. Positive in 50 percent, often high titer.
- Hypergammaglobulinemia. Elevated IgG with polyclonal gammopathy.
- Cryoglobulins. Present in 10 to 15 percent. Associated with more severe systemic disease and lymphoma risk.
- Minor salivary gland biopsy. Focus score of 1 or greater per 4 mm2 confirms diagnosis when antibodies are negative.
You can meet 14.10 without positive antibodies if the biopsy is diagnostic. About 30 percent of Sjogren's patients are seronegative and rely on biopsy or clinical criteria for diagnosis.
Documentation checklist
- Rheumatology clinic notes from at least 12 months, ideally 24 months
- Anti-Ro, anti-La, ANA, rheumatoid factor, complement, quantitative immunoglobulins, cryoglobulins
- Schirmer test results and ocular surface staining (van Bijsterveld or Ocular Staining Score)
- Salivary flow measurement or Wafflemap-1 or Whole Salivary Flow rate
- Minor salivary gland biopsy if performed
- ILD workup: PFTs (FVC, FEV1, TLC, DLCO), HRCT chest
- Renal: urinalysis, urine electrolytes, 24-hour urine protein, serum bicarbonate, creatinine
- Neurologic: EMG/NCS for large fiber neuropathy, skin biopsy for small fiber neuropathy, autonomic testing if dysautonomia is suspected
- Hematologic: CBC, peripheral smear, cryoglobulin studies
- Hepatic: LFTs, autoantibody panel for AIH/PBC, imaging
- Neurocognitive evaluation for Path B CPP domain
- PT/OT functional capacity evaluation for Path B ADL domain
Worked case 1: Aya, 45, Washington, primary Sjogren's with ILD and small fiber neuropathy
Aya has primary Sjogren's with anti-Ro 320 units, anti-La 180 units, ANA 1:640 speckled. She has:
- Sicca complex with abnormal Schirmer (2 mm at 5 minutes bilaterally) and salivary flow 0.05 mL per minute
- NSIP-pattern ILD with FVC 58 percent, DLCO 44 percent, requiring mycophenolate
- Small fiber neuropathy with reduced epidermal nerve fiber density on thigh biopsy (2.1 fibers/mm), disabling burning pain in feet
Constitutional: severe fatigue documented at 10 rheumatology visits, involuntary weight loss of 17 pounds over 12 months. Her attorney filed under Path A: two organ systems (pulmonary is the moderate-severity one, plus neurologic), two constitutional symptoms (severe fatigue, involuntary weight loss). DDS approved at initial in July 2026.
Worked case 2: Renata, 52, Massachusetts, seronegative Sjogren's with cognitive dysfunction and repeated flares
Renata has biopsy-proven Sjogren's (focus score 2.3 per 4 mm2) with negative anti-Ro and anti-La. She has:
- Sicca complex
- Non-erosive inflammatory arthritis with multiple flares
- Recurrent cytopenias (Hgb 9.5, WBC 3.1)
- Documented cognitive dysfunction on neuropsychological evaluation (WAIS-IV processing speed 79, executive function 82)
Constitutional: severe fatigue at every rheumatology visit, malaise documented at 8 visits. Her disease pattern is 4 documented flares over 18 months, no fixed two-organ moderate-severity presentation at any single moment.
Her attorney filed under Path B: repeated manifestations, two constitutional symptoms (fatigue, malaise), one marked functional limitation (CPP domain based on neuropsych). DDS denied at initial. On reconsideration a medical expert reviewed the neuropsych and rheumatology summary letter and reversed to allowance under Path B in October 2026.
Common denial reasons and how to counter them
"Sicca complex only, no systemic involvement"
Counter: submit records documenting the second organ system with objective evidence. If pulmonary, PFTs and HRCT. If renal, urinalysis and metabolic panel. If neurologic, EMG or skin biopsy. Sicca alone is one organ, so a second organ system must be documented.
"Fatigue not severe enough to be constitutional symptom"
Counter: get consistent rheumatology documentation of severe fatigue at multiple visits. Add PRO scores like FACIT-Fatigue. Submit third-party statements from family or coworkers. Ask your rheumatologist to characterize the fatigue as severe in a summary letter.
"Path B marked limitation not established"
Counter: neuropsychological evaluation for CPP domain, functional capacity evaluation for ADL domain, mental health evaluation for social functioning. Third-party statements matter here.
"Diagnosis not established under 14.00D7"
Counter: submit anti-Ro and anti-La titers if positive, or the minor salivary gland biopsy report with focus score. If seronegative and no biopsy, ask your rheumatologist about arranging a minor salivary gland biopsy through an oral pathologist.
Related autoimmune listings
- 14.02 Systemic lupus erythematosus. Same two-path structure. Sjogren's often overlaps with lupus.
- 14.04 Systemic sclerosis (scleroderma). Multiple paths including pulmonary hypertension.
- 14.05 Polymyositis and dermatomyositis. Five paths including proximal weakness and dysphagia.
- 14.06 UCTD and MCTD. Same two-path structure. Used when the picture does not fit a specific disease.
- 14.09 Inflammatory arthritis. RA, AS, PsA. Overlaps with Sjogren's in secondary form.
Sjogren's brain fog: what the neurocognitive data actually shows
Cognitive dysfunction in Sjogren's is real and measurable. Studies using standardized neuropsychological batteries show that primary Sjogren's patients have reduced performance in:
- Processing speed (Symbol Digit Modalities Test, Trail Making Test Part A)
- Working memory and executive function (Trail Making Test Part B, Wisconsin Card Sorting Test, Stroop)
- Sustained attention (Continuous Performance Test)
- Verbal memory (California Verbal Learning Test, Rey Auditory Verbal Learning Test)
Imaging studies show white matter hyperintensities on brain MRI in a substantial portion of primary Sjogren's patients even without focal neurologic deficits. If your CPP domain limitation is the strongest Path B route, ask your neurologist about brain MRI and about referral for a full neuropsychological battery. The battery report is what DDS respects, not screening scores like MoCA or MMSE.
Sjogren's epidemiology and disease burden
Primary Sjogren's syndrome affects an estimated 0.5 to 1 percent of adults, making it one of the more common autoimmune diseases. Women outnumber men roughly 9 to 1. Peak diagnosis age is 40 to 60, though pediatric and elderly cases exist. Because sicca symptoms are often dismissed as normal aging or medication side effects, delays from symptom onset to diagnosis average 4 to 7 years. That diagnostic delay matters for SSDI because SSA needs objective evidence going back through the alleged onset period. Patients who did not have antibody testing early on may have years of undocumented disease activity that a rheumatologist can retrospectively piece together from primary care records.
Systemic involvement rates in primary Sjogren's:
- Arthritis or arthralgias: 50 percent
- Fatigue rated severe: 70 percent
- Peripheral neuropathy: 20 to 25 percent
- Interstitial lung disease: 10 to 15 percent
- Renal tubular acidosis: 5 to 10 percent
- Cutaneous vasculitis: 5 to 10 percent
- Cognitive dysfunction on formal testing: 40 to 80 percent depending on the battery
- MALT lymphoma lifetime risk: 5 percent
Salivary gland ultrasound: the underused diagnostic tool
Salivary gland ultrasound has emerged as a supportive diagnostic tool for Sjogren's. Characteristic findings include:
- Hypoechoic areas in parotid and submandibular glands
- Loss of homogeneous echostructure
- Grade 2 or 3 findings on the OMERACT scoring system
Ultrasound is not part of the 14.10 diagnostic criteria, but a positive ultrasound in a seronegative patient strongly supports the diagnosis and can push DDS toward accepting the biopsy alternative in 14.00D7.
Sjogren's and dysautonomia
Autonomic dysfunction is common in Sjogren's and includes orthostatic intolerance, gastroparesis, neurogenic bladder, cardiovagal impairment, and disturbed sweating. If you have documented dysautonomia (tilt table test, autonomic reflex testing, gastric emptying study), it counts as neurologic organ involvement. Combined with sicca that gives you two organ systems for Path A. Severe orthostatic intolerance that prevents upright activity is a strong ADL argument for Path B.
Treatment options in 2026
Standard 2026 treatment for systemic Sjogren's includes:
- Hydroxychloroquine for musculoskeletal and constitutional symptoms
- Methotrexate or leflunomide for inflammatory arthritis
- Mycophenolate for ILD, renal disease, and cytopenias
- Azathioprine for maintenance immunosuppression
- Rituximab for cryoglobulinemia, severe cytopenias, and select MALT lymphoma
- Belimumab (off-label) for overlapping SLE features
- Iscalimab (anti-CD40) has completed phase 3 trials with promising results
- Symptomatic management for sicca (cyclosporine 0.05 percent ophthalmic, lifitegrast 5 percent ophthalmic, pilocarpine, cevimeline, artificial saliva, humidifiers, punctal plugs, autologous serum tears)
SSA will look at your treatment history to confirm the disease is treated and yet still disabling. A well-documented failure of first-line and second-line therapy is strong support for the case.
What to do this week if you have Sjogren's and think you might qualify
- Get a full rheumatology records package. Every visit, every lab, every imaging report. 14.10 depends on documenting patterns over time.
- Order any missing objective tests. If you have symptoms suggesting a second organ system but no workup has been done, request it. PFTs for pulmonary, urinalysis for renal, EMG for neuropathy.
- Ask your rheumatologist for a summary letter using 14.10 language. Path A or Path B, which organ systems, which constitutional symptoms, which functional limitation for Path B.
Frequently asked questions
Can I qualify with negative anti-Ro and anti-La antibodies?
Yes, if you have biopsy-confirmed Sjogren's with focus score 1 or greater per 4 mm2 on minor salivary gland biopsy. About 30 percent of Sjogren's patients are seronegative. The biopsy is diagnostic when antibodies are negative.
Does dry mouth and dry eye alone qualify for 14.10?
No. Sicca complex alone is one organ system (exocrine/ocular). Path A requires two organ systems with one at moderate severity plus two constitutional symptoms. Path B requires repeated manifestations plus marked functional limitation. Both paths require more than sicca.
What if my Sjogren's is secondary to lupus?
Secondary Sjogren's is evaluated with the primary underlying disease. If your primary diagnosis is lupus, file under 14.02 with the Sjogren's features counting as additional organ involvement. If the sicca is the dominant clinical feature, file under 14.10.
Is Sjogren's brain fog enough for Path B marked limitation in CPP?
Alone it may not be enough. Objective neuropsychological testing documenting marked deficits in processing speed, working memory, or executive function is the strongest support. Rheumatology documentation of cognitive complaints plus neuropsych plus functional evidence together support the CPP marked limitation.
Does small fiber neuropathy count as an organ system?
Yes. Small fiber neuropathy documented by reduced epidermal nerve fiber density on skin biopsy, or by abnormal quantitative sudomotor axon reflex testing, counts as neurologic involvement. Combined with sicca that gives you two organ systems.
Is MALT lymphoma from Sjogren's automatically qualifying?
Not automatically under 14.10. MALT lymphoma may qualify under Section 13.05 (lymphoma) depending on stage, treatment response, and prognosis. It also counts as an organ system involvement for Path A of 14.10.
How do I document severe fatigue when it is subjective?
Consistent mention in clinical notes over multiple visits. PRO scores like FACIT-Fatigue or Fatigue Severity Scale. Functional evidence such as reduced ADL performance and time-limited work capacity. Third-party statements from people who see you regularly.
See If You Qualify